No data to show
XNAS
XYLO
Market cap9mUSD
May 09, Last price
5.20USD
1D
0.00%
1Q
5.91%
IPO
-25.57%
Name
Medigus Ltd
Chart & Performance
P/E
—
P/S
0.11
EPS
—
Div Yield, %
—
Shrs. gr., 5y
64.50%
Rev. gr., 5y
191.47%
Revenues
92m
-0.15%
Net income
-16m
L+56.98%
CFO
-6m
L+10.45%
Dividend
Dec 19, 20220.85 USD/sh
Profile
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 91,724 -0.15% | 91,858 807.87% | |||||||
Cost of revenue | 102,539 | 100,439 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (10,815) | (8,581) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (74) | 111 | |||||||
Tax Rate | |||||||||
NOPAT | (10,741) | (8,692) | |||||||
Net income | (16,025) 56.98% | (10,208) -352.30% | |||||||
Dividends | (1,583) | ||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 466 | 12,567 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 9,084 | 6,742 | |||||||
Long-term debt | 1,272 | 4,036 | |||||||
Deferred revenue | 1 | ||||||||
Other long-term liabilities | 26 | 125 | |||||||
Net debt | (5,947) | (27,407) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (6,247) | (5,656) | |||||||
CAPEX | (51) | (74) | |||||||
Cash from investing activities | (4,063) | (4,476) | |||||||
Cash from financing activities | (524) | 5,410 | |||||||
FCF | (10,591) | (9,614) | |||||||
| Balance | |||||||||
Cash | 12,536 | 25,050 | |||||||
Long term investments | 3,767 | 13,135 | |||||||
Excess cash | 11,717 | 33,592 | |||||||
Stockholders' equity | (80,448) | (56,830) | |||||||
Invested Capital | 122,695 | 121,779 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 632 | 1,626 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (6,836) | (5,344) | |||||||
EV/EBITDA | |||||||||
Interest | 1,532 | 4,080 | |||||||
Interest/NOPBT | |||||||||